Contacts: Deborah Carty Mark Vincent NexMed, Inc. Euro RSCG Life NRP 609-208-9688, ext: 159 (212) 845-4239 dcarty@nexmed.com Mark.Vincent@eurorscg.comLicense, Supply and Distribution Agreement • July 6th, 2004 • Nexmed Inc • Pharmaceutical preparations
Robbinsville, NJ, July 6, 2004 -- NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT(R) drug delivery technology, today announced that it has entered into a license, supply and distribution agreement with Schering AG, Germany (FSE: SCH, NYSE: SHR). This agreement provides Schering with exclusive commercialization rights to Alprox-TD(R) in Europe, Russia, the Middle East, South Africa, Australia and New Zealand. NexMed will retain the intellectual property relating to Alprox-TD(R) and will manufacture and supply the product to Schering. Under the terms of this partnership, NexMed will receive future milestone payments as well as a share of the revenue through transfer price payments based on the supply of Alprox-TD(R). The overall financial terms are intended, depending upon performance levels, to approximate an equal sharing of the value of the product.
